Abstract
Specimens from HIV-positive patients with oral candidosis were taken for culture, species identification and azole susceptibility testing, which was correlated with treatment outcome. Of 921 specimens, 95 yielded non-albicans species, mainly from patients with low CD4 lymphocyte counts and extensive previous azole exposure. Most non-albicans isolates were from specimens co-infected with Candida albicans, complicating the interpretation of in-vitro susceptibility results, which accurately predicted antifungal failure when the non-albicans species was isolated alone. Eighty-five non-albicans isolates were resistant to fluconazole in vitro. Of 149 courses of azole therapy prescribed, 115 failed to clear non-albicans candidosis clinically. Culture media that discoloured in the presence of non-albicans colonies might, therefore, guide therapy.
Cite
CITATION STYLE
Cartledge, J. D., Midgley, J., & Gazzard, B. G. (1999). Non-albicans oral candidosis in HIV-positive patients. Journal of Antimicrobial Chemotherapy, 43(3), 419–422. https://doi.org/10.1093/jac/43.3.419
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.